Matthew A. Gubens
Expertise in
16
conditions

Dr. Matthew A. Gubens

Oncology
1600 Divisadero St., Fourth Floor, 
San Francisco, CA 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
1600 Divisadero St., Fourth Floor, 
San Francisco, CA 

Overview

Dr. Matthew Gubens is a thoracic oncologist who cares for patients with lung cancer. He specializes particularly in treating non-small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma, and mesothelioma. In his research, Gubens studies new treatment strategies for lung cancer and other malignancies of the chest area. Gubens earned his medical degree at Stanford University School of Medicine. He completed a residency in internal medicine at UCSF and a fellowship in medical oncology at Stanford. He also earned a master's degree in health policy and management at the Harvard T.H. Chan School of Public Health. Gubens is a member of the American Society of Clinical Oncology, International Association for the Study of Lung Cancer and International Thymic Malignancy Interest Group.

Dr. Gubens is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thymic Epithelial Tumor, and Lung Adenocarcinoma.

Dr. Gubens is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 6 clinical trials. Dr. Gubens is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Med/Medical Oncology, Medical Oncology

Fellowships

Stanford University School of Medicine, Oncology

Hospital Affiliations

Marinhealth Medical Center
Ucsf Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Thoracic Surgery and Oncology Clinic
1600 Divisadero St., Fourth Floor, San Francisco, CA 94143
Other Locations
Thoracic Surgery and Oncology Clinic
1825 Fourth St., Sixth Floor, San Francisco, CA 94158

Additional Areas of Focus

Dr. Gubens has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Biological
Study Drugs: TG4010, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: March 04, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Enrollment Status: Completed
Publish Date: January 12, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

74 Total Publications

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
Journal: Oncoimmunology
Published: September 02, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (10.1 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. John C. Chan
Oncology | Obstetrics and Gynecology
Expertise in
22
conditions
Dr. John C. Chan
Oncology | Obstetrics and Gynecology
Referral may be required
Before you request

John C.K. Chan, MD Private Practice

1100 Van Ness Ave, 4th Fl, 
San Francisco, CA 
 (1.0 miles away)
415-600-0930
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Chan is an Oncologist and an Obstetrics and Gynecologist practicing medicine in San Francisco, California. Dr. Chan is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy. Dr. Chan is board certified in Obstetrics And Gynecology - Board Certified , OB & Gyn (Sub: Gynecologic Oncology), Gynecologic Oncology - Board Certified, and Obstetrics & Gynecology. Dr. Chan is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (28.1 miles away)
650-498-6000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.

Frequently Asked Questions about Dr. Matthew A. Gubens

How do I make an appointment with Dr. Matthew A. Gubens?

You can book an appointment with Dr. Matthew A. Gubens by calling their office at 415-885-3882. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew A. Gubens a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew A. Gubens is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew A. Gubens specialize in?

While Dr. Matthew A. Gubens is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Thymic Epithelial Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Matthew A. Gubens participate in research or clinical trials?

Yes. Dr. Matthew A. Gubens has published 74 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Matthew A. Gubens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew A. Gubens accept my insurance?

Dr. Matthew A. Gubens accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 415-885-3882 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gubens's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile